June 9 (Reuters) - Beyondspring Inc:
* BEYONDSPRING’S PROTECTIVE-2 (STUDY 106) PHASE 2 TRIAL FOR CHEMOTHERAPY-INDUCED NEUTROPENIA SHOWS POSITIVE RESULTS IN CHEMOTHERAPY OPTIMIZATION WITH POTENTIALLY BETTER CLINICAL OUTCOMES Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.